Tesamorelin can cause water retention, as it stimulates the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) pathway, which affects how the body regulates sodium, fluids, and tissue hydration [1-6]. Tesamorelin causes water retention primarily by increasing hormonal activity related to the body's water and sodium balance. Increased GH and IGF-1 activity can lead to mild fluid accumulation in some individuals, presenting as edema, puffiness, bloating, or mild tissue swelling, which is the buildup of fluid in the body's tissues.
Clinical trials have repeatedly reported mild edema and fluid retention in some individuals using tesamorelin. In Phase III studies conducted by Falutz et al. (2007, 2010), peripheral edema, swelling, and injection site reactions were among the more frequently reported adverse events during treatment [2,3]. Long-term safety studies have also noted mild fluid retention symptoms in some participants, however, these effects were generally considered manageable and not severe [4].
Water retention associated with tesamorelin is typically mild and transient, not dangerous. Some individuals may notice:
- Mild swelling of the hands, feet, or ankles
- Facial swelling
- Temporary fluctuations in body weight
- Feeling of tightness in rings, shoes, or clothes
- Mild bloating
The severity of fluid retention can vary depending on factors such as dose, individual sensitivity to GH signaling, baseline metabolic state, kidney function, and the degree of IGF-1 level increase during therapy [1–6]. Individuals experiencing a greater increase in IGF-1 may be more susceptible to edema-related symptoms.
Importantly, most studies on tesamorelin have demonstrated that fluid retention did not typically lead to significant cardiovascular or metabolic complications in appropriately qualified participants [2–5]. Overall, clinical trials have described tesamorelin as relatively well-tolerated despite occasional symptoms of edema or water retention.
To limit water retention during tesamorelin therapy, the following supportive strategies are often discussed:
- Monitoring sodium and salt intake
- Maintaining adequate hydration
- Limiting excessive alcohol consumption
- Monitoring IGF-1 levels during treatment
- Dosage adjustment under medical supervision if symptoms worsen
- Regular physical activity supporting circulation
Because tesamorelin affects hormonal and metabolic pathways, persistent or worsening edema should be evaluated by a physician to rule out an excessive GH or IGF-1 response, cardiovascular issues, kidney dysfunction, or other underlying conditions.
A meta-analysis conducted by Badran et al. (2026) also confirmed that tesamorelin can cause adverse events such as joint pain, muscle pain, tingling, injection site reactions, and edema-related symptoms, although serious adverse events remained generally rare [6].
Generally speaking, the water retention associated with tesamorelin appears to stem primarily from the activation of the GH-IGF-1 pathway, which temporarily alters the body's handling of sodium and fluids. In most clinical studies, this effect was mild, manageable, and often considered less significant than the benefits observed in visceral fat reduction and improved metabolic health in many participants.
Disclaimer
The content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin affects hormonal pathways and can cause fluid retention and other adverse effects that require medical monitoring. Individuals experiencing persistent swelling, water retention, or other concerning symptoms should consult a qualified healthcare professional.
References
- Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Tesamorelin Overview
- Falutz J, Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
- Falutz J, Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
- Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
- Rahman F, McLaughlin, T., Mesquita, P., et al. (2023). Effect of Tesamorelin in People With HIV With and Without Dorsocervical Fat: Post Hoc Analysis of a Phase III Double-Blind Placebo-Controlled Trial. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515
- Badran AS, Helal, A., Shata, K. S., & Ayesh, H. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice, 20(1), 2–12. https://doi.org/10.1016/j.orcp.2026.01.002